Stocktoria
Passage BIO, Inc. PASG
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-02-28
Passage BIO, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $23.3M | $40.2M | $61.4M | — | — |
| Operating income | -$49.3M | -$70.4M | -$108.4M | -$138.4M | -$185.7M |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$45.5M | -$64.8M | -$102.1M | -$136.1M | -$185.4M |
| EPS (diluted) | $-14.35 | $-21.04 | $-1.86 | $-2.50 | $-3.48 |
| Operating cash flow | -$31.5M | -$48.0M | -$78.3M | -$118.2M | -$126.9M |
| Cash & equivalents | $46.3M | $37.6M | $21.7M | $34.6M | $129.0M |
| Total assets | $62.3M | $102.4M | $150.5M | $243.5M | $355.1M |
| Total liabilities | $43.5M | $41.2M | $39.3M | $42.2M | $36.4M |
| Shareholders' equity | $18.8M | $61.3M | $111.3M | $201.4M | $318.7M |
Source: SEC EDGAR filings · CIK 0001787297 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.